Key takeaways
- • Frequency: Common — 7-11% in trials.
- • Trial reference: STEP-1 (semaglutide) (7-24%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Two mechanisms: slowed gut motility from the GLP-1 receptor effect, plus reduced food intake (less bulk → less stimulus for bowel movements).
How to manage it
- Increase water intake to 64-100 oz daily
- Add 25-30g daily fiber — start with soluble fiber (oats, chia, psyllium husk) to avoid bloating
- Magnesium citrate or stool softener (Colace) generally safe — confirm with prescriber
- Walk 30+ min daily — physical activity stimulates bowel motility
- Avoid stimulant laxatives long-term (dependency risk)
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • No bowel movement for 5+ days
- • Severe abdominal pain or distension
- • Vomiting + constipation together (bowel obstruction risk)
- • Blood in stool or rectal bleeding
Drug-specific notes
- Wegovy: Constipation ~24% at peak; common with reduced food intake
- Zepbound: Constipation ~17% at maximum doses
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Gastrointestinal
Gallbladder issues on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)